EARLY 2025 MILESTONES

Cumberland’s business strategy has been to acquire and commercialize a portfolio of branded pharmaceuticals that we can grow through our dedicated sales organization domestically and through our partners internationally. We’ve also built an internal development capability, which enables us to develop and register new medicines, establishing a long-term pipeline for our business. We recently reported […]

November 2024 Updates, Highlighting Key Clinical and Business Developments

We are pleased to report several significant milestones that reinforce our mission of working together to provide unique products that improve the quality of patient care. Our latest updates include important research findings, growing Medicaid coverage and expanded product access. In October, we announced new real-world outcomes research comparing Caldolor® to its key competitor – […]

Second Quarter 2024 Updates, Including Double-Digit Revenue Growth

We were pleased to report that Cumberland delivered a strong financial performance for the second quarter. Our line of FDA-approved brands delivered just under $10 million in net revenues, which represented 16% in sequential growth from the first quarter of the year. During the quarter we remained dedicated to advancing our mission of working together […]